DIRUI(SZ:300396)2026-01-30 09:12Financial Performance - The company expects a net profit of approximately -35,000 million CNY for the fiscal year 2025, compared to -18,000 million CNY in the same period last year, indicating a significant decline [5]. - The net profit after deducting non-recurring gains and losses is projected to be around -36,000 million CNY, down from -18,500 million CNY year-over-year [5]. - The decline in performance is attributed to intensified market competition, asset impairment, and adjustments in product pricing, which negatively impacted revenue and profit margins [8]. Cash Flow and Cost Management - The company has improved cash flow significantly, with collections and cost control measures leading to a substantial increase compared to the previous year [9]. - The company is committed to enhancing its product intelligence and market expansion while continuing to strengthen internal controls and cost reduction efforts [10]. International Expansion - The company has been actively expanding its international market presence, maintaining a solid foundation in over 120 countries, and plans to deepen its focus on 10 selected countries as part of its "2+2+10" international strategy [10]. Product Development and Innovation - The company is focusing on technological innovation and product development, with 14 new products, including the CS-1300A automatic biochemical analyzer, launched during the reporting period [10]. Earnings Forecast and Investor Advisory - The company has communicated with its accounting firm regarding the earnings forecast, and there are no significant discrepancies reported [6]. - The financial data presented is preliminary and subject to final confirmation in the official 2025 annual report [11]. - Investors are advised to exercise caution and consider investment risks based on the preliminary earnings forecast [11].